Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$49.00
Provider: New Constructs, LLC
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Watson Pharmaceuticals Inc Announces Sale of Rugby OTC Product Trademark and Assets to Major Pharmaceuticals


Monday, 29 Oct 2012 10:04am EDT 

Watson Pharmaceuticals Inc announced that it has sold its Rugby over-the-counter (OTC) pharmaceutical products and trademarks to The Harvard Drug Group, LLC, distributor and provider of private label OTCs and generic prescription products, for approximately $117 million. The transaction received clearance from the U.S. Federal Trade Commission on October 19, 2012 under requirements of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act). The Rugby OTC portfolio includes more than 250 SKUs of cough and cold, allergy, pain relief, nausea relief, nicotine gum, vitamin and nutritional supplement products which are sold through various healthcare outlets across the United States. 

Company Quote

219.72
3.35 +1.55%
23 Jul 2014